Kornimate/medical-research-clean huggingface dataset:
a patient portal tool, e-assist, for supporting crc screening

Conditions: Colorectal Cancer

Summary: to compare patient perceptions, intent to screen, and screening use among those using a patient portal with and without a colorectal cancer (crc) screening decision support tool, e-assist. to evaluate whether the effectiveness of e-assist is moderated by multi-level factors, including patient health literacy, decision-making preference, and crc screening decision stage. to assess program impact and create an implementation guide for e-assist by combining results from aims 1 \& 2, a program implementation analysis/process evaluation and the perspectives of staff from future diverse implementation sites including small primary care practices, university-based primary practices and federally-qualified health centers.

during initial project period, the content was developed for the online e-assist tool using messages and tools developed under prior nci-funded applications combined with newly developed messaging specific to this application. throughout development, the principal investigator will seek input and guidance from a quality improvement team at the henry ford health system (hfhs) (i.e., the local performance site) that is tasked with patient portal innovation for meaningful use. once finalized, the effectiveness of e-assist will be evaluated using a three-arm, practical randomized trial. trial participants will be randomized to one of the following three groups: 1. e-assist: colon health (treatment arm) \[n = 900\] 2. healthwise educational program (active control) \[n = 900\] 3. usual care control (observational only) \[n = 900\] for the evaluation, the investigators employ an intent-to-treat design with primary effectiveness measured by electronic health record (ehr)-documented crc screening use. secondary outcomes of interest include patient-reported crc screening intent, perceived barriers to and support for crc screening as well as perceived susceptibility and screening benefits. results from all analyses will be used to develop an implementation guide for the dissemination and implementation of e-assist among diverse primary care practices.

Eligibility criteria:
inclusion criteria: -crc screening recommendation via colonoscopy and/or stool cards at time of primary care appointment. receiving care in a hfhs primary care clinic and activated mychart account. exclusion criteria: * ehr-documented colonoscopy in the past 10 years, sigmoidoscopy in the past 5 years, or fecal occult blood test (fobt) or fecal immunochemical test (fit) in the past 12 months. * elevated risk for crc (i.e., personal or family history of crc, those with prior polyps, or a history of inflammatory bowel disease, familial adenomatous polyposis, or hereditary nonpolyposis).

Keywords: colorectal cancer screening crc screening rectum colon screening populations at risk crc colorectal cancer (crc)
physiotherapy in assisted reproductive treatment

Conditions: Infertility

Summary: research examines the effect of physiotherapy on treatment success by assisted reproductive technologies. it is based on a treatment of infertility by physiotherapeutic intervention after which the participants will undergo a treatment of assisted reproductive technologies (in vitro fertilisation). the work hypothesis is that physiotherapeutic treatment of female infertility improves the chances of conception by assisted reproductive technologies.

this is an intervention study which also shows how physiotherapists can improve cooperation between two professionals (gynaecologists and physiotherapists). the study is based on physiotherapeutic intervention which consist of three months of physiotherapy. the physical therapy program consists of 10 individual therapeutic sessions. every session lasts 45 minutes, frequency of the first six sessions is once a week, frequency of the last four sessions is once every two weeks. the duration for each participant is three months. the participants will be examined by the physiotherapist during first and last therapy session and they will be asked to fill questionnaires and to keep records of their exercises, period and ovulation in their diaries. there will be three validated questionnaires: the 36-item short form health survey, which measures a health-related quality of life, also the state-trait anxiety inventory which measures state and trait anxiety and the last one is the female sexual function index which measures sexual function in women. the participants will be asked to do physiotherapeutic exercises as self-treatment every day according to a handout they get at the first therapy session. the results from intervention group will be compared to control group in which we use retrospective data (from year 2019) from centre of assisted reproduction of general university hospital in prague. we will compare the number of women treated by assisted reproductive technologies but without physiotherapeutic intervention. to sum up, in this study we compare the number of women who conceived following the assisted reproductive technologies with and without physiotherapeutic intervention.

Eligibility criteria:
inclusion criteria: * nullipara * age (18-39 years) * in the past at minimum one failed attempt of conception by assisted reproductive technologies * duration of infertility at minimum one year, * body mass index (bmi) 18,5-34,9 according to the world health organization exclusion criteria: * acute or chronic serious disease * taking oral contraceptive pills for the last six months

Keywords: physiotherapy assisted reproductive technologies conception
local study of akatinol memantine in vad in russia

Conditions: Vascular Dementia

Summary: the study evaluates the clinical efficacy and safety of akatinol memantine 20 mg (single-doses) vs. akatinol memantine 10 mg (double-doses) in patients suffering from moderate and moderately severe vascular dementia.


Eligibility criteria:
inclusion criteria: * written informed consent obtained from the patient or his/her legal representative if the patient is declared incapable by a court decision. * understanding of study procedures and willingness to abide to all procedures during the course of the study by the patient or his/her legal representative. * male and female patients from 50 to 85 years of age (inclusive) suffering from moderate and moderately severe vascular dementia. * mini-mental state examination (mmse) test total scores of 10 to 20. * hachinski's ischemic score (his) of 7 or higher point. * availability in the anamnesis of instrumental confirmation of the diagnosis (data methods of neurovisualization - ct or mrt). * for females: menopause or inability to conceive due to other reasons (hysterectomy, etc.). * availability of a relative or legal representative who lives with the patient, monitors him/her and cares for the patient. exclusion criteria: * alzheimer's disease or secondary types of dementia. * epilepsy, seizures, schizophrenia, other psychoses, bipolar disorder, alcoholism, drug abuse (including the history thereof). * other clinically significant neurological or psychiatric disorders. * severe depression (hamilton score, ham-d \> 18 points). * severe, unstable or decompensated physical disease (including clinically significant laboratory abnormalities) potentially affecting the trial findings. * contraindications to oral drug intake during the time period determined by the study protocol. * known hypersensitivity to the investigational product or any of its ingredients. * administration of nootropic, anti-dementia and typical antipsychotic drugs, tricyclic antidepressants, long-acting benzodiazepines, nmda receptor antagonists (amantadine, ketamine, dextromethorphan) for 1 month before the enrollment and during the study. * for females: pregnancy and breastfeeding. * evidence or suspicion that the patient might not comply with the study directive. * any reason or contraindication which in the investigator's opinion precludes participation in the study. * patient is direct relative of an employee of the study site or merz pharma llc. * previous participation in this clinical study. * participation in another clinical trial within the last 12 weeks prior to screening or ongoing participation in a study.
clinical assessment of indirect restoration fabricated from nano hybrid composite blocks versus ceramic blocks in badly broken teeth one year follow up

Conditions: Teeth Restoration

Summary: the aim of the study is to compare one-year clinical performance of indirect restoration fabricated from nano hybrid composite cad cam blocks and ceramic blocks

this research is conducted for comparing the clinical efficacy of nano hybrid composite blocks and ceramic blocks ., the choice of nano hybrid composite blocks based on the claim of the manufacturer, as it's considered to be promising , nano hybrid composite blocks has the highest fillers content (86% by weight), resembles natural teeth perfectly , excellent physical values for flexural strength and abrasion, no firing required (a real one step ), can be processed using any conventional milling unit, can be finished and polished optimally, ideal for grinding even in cases with thin edges.

Eligibility criteria:
inclusion criteria: * patients with badly broken vital teeth * young adult males or female * good oral hygiene measures * cooperative patients approving to participate in the study exclusion criteria: * patients with a compromised medical history. * severe or active periodontal disease * severe medical complications * lack of compliance * endodontically treated teeth
survey of post-acute inpatient rehabilitation safety concerns in participants with cancer

Conditions: Malignant Neoplasm

Summary: this trial studies a survey of post-acute inpatient rehabilitation safety concerns in participants with cancer. collecting patients' feedback via surveys may help doctors to learn more about the safety concerns that patients have when they are discharged from the acute inpatient cancer rehabilitation unit.

primary objectives: i. assess patients' perceptions regarding safety after acute inpatient rehabilitation at discharge and after approximately one month from discharge date. secondary objectives: i. assess patient's perception of factors impacting continuity of care at discharge and after approximately one month from discharge date. ii. determine the frequency of reported falls and the circumstance surrounding reported falls during hospitalization and within approximately one month from discharge date. iii. determine the frequency of reported near falls and the circumstance surrounding reported near falls within approximately one month from discharge date. iv. identify demographic and clinical characteristics associated with feeling safe and unsafe. outline: participants complete surveys over 15 minutes at 1-2 days before discharge and at 1 month after discharge.

Eligibility criteria:
inclusion criteria: * all patients who are discharged from the acute cancer inpatient rehabilitation unit to personal residence (house, apartment, condominium, hotel, assisted living, etc.) * patients who provide informed consent * english-speaking participants exclusion criteria: * patients discharged to another hospital or health facility (skilled nursing facility \[snf\], long term acute care hospital \[ltach\], inpatient hospice, etc.) * patients with moderate to severe cognitive deficits as determined by speech language pathologist and/or rehabilitation physician * patients who were re-hospitalized at any time during study period (since completion of first survey in the hospital and discharged from the hospital until approximately one month after discharge * patients who were readmitted to acute inpatient rehabilitation service and previously completed both surveys
characterization of a portable solid-state breath acetone testing device for real-time ketosis status

Conditions: Ketogenic Dieting; Ketosis

Summary: the primary purpose of this study is to characterize the performance and utility of a novel breath acetone meter developed by readout, inc.


Eligibility criteria:
inclusion criteria: * ketogenic diet cohort: currently following a ketogenic or low-carbohydrate diet defined as less than 30 grams per day (ketogenic) or less than 100 grams per day (low-carbohydrate) as estimated by the individual. subjects must have been following the diet before the beginning of the study period and must continue with the diet throughout the duration of the trial. * high-carbohydrate diet cohort: currently following a diet that does not restrict dietary carbohydrate. carbohydrate consumption should be greater than 100 grams per day as estimated by the individual. subjects must have been following the diet before the study period and must continue with the diet throughout the duration of the trial. exclusion criteria: * type-1 diabetes * insulin-dependent type-2 diabetes * history of diabetic ketoacidosis * currently taking warfarin or other blood thinners * currently taking a sodium-glucose cotransporter-2 (sglt2) inhibitor * currently taking disulfiram * unwilling to maintain their diet during the study period * unwilling to test blood and breath ketones five times per day * non-english speaking * persons who are unable or unwilling to follow the study protocol or who, for any reason, the research team considers not an appropriate candidate for this study, including non-compliance with screening appointments or study visits.
the efficacy and safety of taf vs other nas in patients with lvl

Conditions: Chronic Hepatitis b; Cirrhosis Due to Hepatitis B

Summary: patients with chronic hepatitis b should maximize the inhibition of hbv replication, which could reduce the incidence of liver cancer and liver disease-related complications. however, after 96 weeks of treatment with the first-line drugs, entecavir or tenofovir disoproxil fumarate, a certain proportion of patients still had low levels of hbv replication. tenofovir alafenamide fumarate is a newly marketed anti-hepatitis b drug that is currently considered to be non-inferior to tenofovir disoproxil fumarate and safer bone and renal effects. therefore, this research was put forward to investigate whether tenofovir alafenamide fumarate replacement for hepatitis b had a higher virological response rate and safety in patients with low levels of virus after 48 weeks of treatment with entecavir and tenofovir disoproxil fumarate.

patients who meet the inclusion and exclusion criteria will be enrolled into the research. the participants will voluntarily choose to enter the experimental group or the control group with full informed consent. the control group will continue with the original regimen, while the study group will switch to tenofovir alafenamide fumarate antiviral therapy. each group will enroll 100 participants.

Eligibility criteria:
inclusion criteria: * hbsag positive for over half a year; * age from 18 to 80 years old; * entecavir (0.5mg qd) or tenofovir disoproxil fumarate (300mg qd) for 48 weeks or more; * hbv dna level was between 20iu/ ml-2000 iu /ml (cobas, taqman). exclusion criteria: * low-level viremia of hbv caused by non-standard medication; * serum total bilirubin is more than 2 times the upper limit of normal (uln), or alt or ast is more than 5uln, or serum albumin is less than 30g/l; * overlap with hav, hcv, hdv, hev or hiv infection; * other liver disease: drug liver disease, alcoholic liver disease, autoimmune liver disease, genetic metabolic liver disease, etc.; * decompensated cirrhosis or liver cancer; * kidney damage, or autoimmune disease, or other organ failure; * combination of entecavir or tenofovir disoproxil fumarate ; * interferon therapy within half a year; * entecavir (0.5mg qd) or tenofovir disoproxil fumarate; * investigator considering inappropriate.
aminoglycoside plasma level measurement in neonates with infection

Conditions: Nephrotoxicity; Ototoxicity

Summary: the aim of this study is to determine whether the plasma concentration of aminoglycoside in indonesia neonates with infection are within safe and effective range and its association with cochlear toxicity and nephrotoxicity.

aminoglycosides are toxic antibiotics, but they are urgently needed to treat newborns with severe infections. aminoglycosides are well known for their nephrotoxicity and ototoxicity, meanwhile the renal function of the newborns is not yet fully developed.the aminoglycoside dosage currently applied in indonesia is derived from studies done in caucasian populations. the safety and efficacy of this dosage regimen, however, have never been evaluated till date. the pharmacokinetic profile of drugs may vary between populations and this may be influenced by genetic factors, lifestyle, drug interactions, etc. the detection of aminoglycoside toxicity in newborns is usually problematic. the present study aims to know the proportion of nephrotoxicity and ototoxicity in newborns in the cipto mangunkusumo hospital treated with gentamicin or amikacin in relation to their trough serum concentration. the serum level of gentamicin and amikacin is assumed to be safe if the trough serum concentrations are \< 2 mcg/ml and effective if its is between 5-12 mcg/ml. for amikacin the desired trough serum concentrations are \<10 mcg/ml and the peak is between 20-30 mcg/ml. the nephrotoxicity was assessed by measuring the level of kidney injury molecule-1 in urine while the ototoxicity was assessed by distortion product otoacoustic emission (dpoe) instrument.

Eligibility criteria:
inclusion criteria: * neonates with infection treated with gentamicin or amikacin exclusion criteria: * neonates who hypersensitive to gentamicin and amikacin * neonates who also treated with other nephrotoxic drugs (vancomycin, furosemide, amphotericin b, meropenem)

Keywords: aminoglycoside kim-1 dpoae nephrotoxicity ototoxicity
relative bioavailability of olodaterol and fluconazole

Conditions: Healthy; Pulmonary Disease, Chronic Obstructive

Summary: this clinical trial is intended to investigate a possible effect of the cyp 2c9 inhibitor fluconazole on the bioavailability of olodaterol


Eligibility criteria:
inclusion criteria: healthy male and female volunteers
clinical study for adaptive deep brain stimulation (adbs)controlled by intracerebral activity in parkinson's disease

Conditions: Advanced Parkinson's Disease

Summary: despite its therapeutic effectiveness in parkinson's disease (pd) the current deep brain stimulation (dbs) strategy could achieve an even better clinical result by adapting to patient's condition. as intracerebral activity analyzed by recording local field potentials (lfps) from dbs electrodes correlates to pd symptoms, a new stimulation approach would be an "intelligent" adaptive dbs system able to change stimulation settings automatically to the patient's needs using lfps as control variable.

despite their proven efficacy in treating parkinson's disease (pd), deep brain stimulation (dbs) systems could be further optimized to maximize treatment benefits. in particular, because current dbs strategies based on fixed stimulation settings leave the typical parkinsonian motor fluctuations and rapid symptom variations partly uncontrolled, research has focused on developing a novel adaptive dbs (adbs) system able to adapt moment-by-moment to the patient's clinical condition. adbs consists of a simple closed-loop model designed to measure and analyze a control variable reflecting the patient's clinical condition to change stimulation settings and send them to an "intelligent" implanted stimulator. intracerebral activity analyzed by recording local field potentials (lfps) from electrodes implanted for dbs in the past 15 years has helped in clarifying basal ganglia pathophysiology and its relation to pd symptoms. many lfp studies have revealed unknown functions of basal ganglia in pd patients during the execution of motor, cognitive, and behavioral task showing the existence of a "code" in lfp oscillations corresponding to the of patient's clinical condition. lfp-clinical correlations should provide the rationale for developing and implementing new adbs devices able to adapt stimulation parameters moment-by-moment to the individual patient's needs using lfps as a control variable for feedback.

Eligibility criteria:
inclusion criteria: each patient affected by parkinson's disease and implanted with dbs electrodes, following the inclusion criteria of l.i.m.p.e., 2003
value of genetic counseling and testing for patients who would like to know more about their personal risk of amd

Conditions: Age-Related Macular Degeneration; Choroidal Neovascularization; Genetic Counseling

Summary: the goals of this study are: to assess the impact of genetic testing based on how it alters behaviors, to assess the utility of serum biomarker measurement in combination with genetic testing, to assess the utility of genetic counseling in personal analysis of risk for age-related macular degeneration (amd), and to assess the impact of presymptomatic genetic testing for choroidal neovascularization (cnv).


Eligibility criteria:
inclusion criteria: * caucasian (this particular genetic test is only validated in caucasians) participants can have a positive family history of amd but this is not necessary. exclusion criteria: * individuals with a personal history of amd are not eligible. non-caucasian individuals are not eligible. employees of the moran eye center are not eligible. * individuals with a personal history of previous amd genetic risk testing are not eligible. * individuals with a major psychiatric disorder
efficacy of muscle energy techniques in the treatment of chronic non-specific low back pain

Conditions: Low Back Pain, Mechanical

Summary: chronic non-specific low back pain is characterized as a tension, soreness and stiffness. various studies, defined met as a manual medicine treatment procedure that involves the voluntary contraction of the subject's muscle in a precisely controlled direction, at varying levels of intensity, against a distinctly executed counterforce applied by the therapist.

chronic non-specific lbp is located in region below lower costal margins and above inferior gluteal margins with or without any referred pain in legs, an essentially non-attributable to any specific cause. it may lasting for more than 7-12 months and affect individual over a long period of time once in a lifetime at least. mets is useful in increasing extensibility and range of motion of various joints and provides good results in the patients with back pain. these techniques are used as the treatment of weakened muscles, restricted joints, reducing pain reliving muscle tension \& spasm, \& increased strength of the muscle. met is a verstile, safe, gentle technique traditionally used to address muscular strain, pain, local edema and joint dysfunction. it was reported that post isometric relaxation is considered a highly effective therapy for back dysfunction patients.

Eligibility criteria:
inclusion criteria: 1. age: 18 - 45 years 2. gender : both genders 3. low back pain of more than 3 months duration 4. odi score between 20-80% 5. bmi: 25-29 kg/m2 6. vas: initial pain score \> 3 7. pain localized to lower lumbar region 8. decreased lumbar rom exclusion criteria: 1. red flag signs of low back pain (metabolic bone disease, malignancy, cardiovascular disorder, pregnancy) 2. patient with paraesthesia or numbness 3. disturbed reflexes (hypo/hyper reflexia) 4. motor weakness 5. h/o low back surgery 6. h/o recent trauma \< 2 months 7. h/o rheumatoid arthritis, osteoporosis and fracture 8. joint hyper mobility. 9. psychological mental disorders

Keywords: muscle energy technique physical therapy pain functional disability fear avoidance beliefs quality of life range of motion